Listeria Monocytogenes Infection Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 452.30 Million |
| Market Size (2029) | USD 559.51 Million |
| CAGR (2024 - 2029) | 4.35 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Listeria Monocytogenes Infection Treatment Market Analysis
The Listeria Monocytogenes Infection Treatment Market size is estimated at USD 452.30 million in 2024, and is expected to reach USD 559.51 million by 2029, at a CAGR of 4.35% during the forecast period (2024-2029).
Listeriosis is a rare but serious infectious disease caused by the bacterium Listeria monocytogenes. The increasing global incidence of listeria monocytogenes infections plays a pivotal role in driving the treatment market for this bacterial pathogen. Several factors contribute to this trend, including heightened awareness, advancements in diagnostic technologies, and the resulting prompt identification and treatment of cases.
Vulnerable populations, such as pregnant women, elderly and immunocompromised individuals, are at a higher risk of severe complications from Listeria infections. The need for effective treatments in these populations drives market growth. Pregnancy-associated listeriosis is a severe infectious disease and potentially leads to fetal/neonatal fatal. For instance, one of the retrospective cohort study that published by the BMC Pregnancy and Childbirth in March 2022, which states that Pregnancy-associated listeriosis poses severe risks to neonates, particularly those who are outborn, have low birth weights, or are of low gestational age. It's crucial to prioritize timely detection and treatment for these vulnerable neonates.
Moreover, prolonged outbreak of listeria monocytogenes ST173 linked to consumption of food products is a mjor factors that drive the demand for the treatment of listeria monocytogenes infection. Such as in June 2024, European Food Safety Authority, published data that between 2012 and 2024, 73 cases of listeria monocytogenes ST173 infections detected in Belgium, Czechia, Germany, Finland, Italy, the Netherlands and in the United Kingdom. The source states that individuals over the age of 60 constitute the most impacted. Case interviews also reveal that the majority of affected patients consumed a range of fish products prior to falling ill.
Thus, by leveraging the insights from the European Food Safety Authority data and responding proactively to the identified trends and risk factors associated with listeria monocytogenes infections in the elderly population, stakeholders in the healthcare, and pharmaceutical can drive innovations in treatment modalities, improve patient outcomes which in trun drive the market growth.
However, the absence of specific and targeted treatment options for different strains and manifestations of listeria monocytogenes infections can hinder effective disease management.
Listeria Monocytogenes Infection Treatment Market Trends
Drug Segment is Expected to Dominate the Listeria Monocytogenes Infection Treatment Market during the Forecast Period
Listeria monocytogenes is a foodborne pathogen that causes septicemia, meningitis and chorioamnionitis and is associated with high mortality. Antibiotics are the primary treatment for listeria monocytogenes infections. In term of drug class, the listeria monocytogenes infection treatment market is segmented into sulfonamide antibiotics, ampicillin, gentamicin, vancomycin and others.
Key drivers fueling the growth of this drug segment during the forecast period include its proven effectiveness against listeria, its ability to penetrate cells and eliminate the bacteria, its synergistic benefits when combined with other antibiotics, its widespread adoption for treating listeriosis, and endorsements from reputable organizations advocating its efficacy.
Antibiotic such as ampicillin is highly effective against listeria monocytogenes, as this bacterium is generally susceptible to beta-lactam antibiotics like ampicillin. According to National Organization for Rare Disorders, Inc., the most prescribed treatment for listeria monocytogenes infectionis intravenous ampicillin. For affected individuals who cannot tolerate B-lactam antibiotics (such as ampicillin), trimethoprim-sulfamethoxazole is recommended.
Moreover, antibiotic like ampicillin is often used in combination with gentamicin for more severe cases of listeria infections, as the combination exhibits synergistic effects against the pathogen. For instance, in January 2023, a study was published in IDCases, which states that combination therapies, such as adding gentamicin to ampicillin, have been reported to be most effective against the listeria monocytogenes bacterium. Such publishing of studies encouraging healthcare professional to adopt the combination theray to treat the infection more effectively and subsequently boosting the demand for this drug treatment.
Thus, such recommendation from the established organization is likey to drive the segment growth during the forecast period.
North America is Expected to Dominate the Listeria Monocytogenes Infection Treatment Market
North America is expected to hold a significant share owing to the increase in the outbreak of listeria monocytogenes infection, adoption of advances diagnostic technologies, such as rapid molecular testing and strong regulatory frameworks and enforcement of food safety standards can help reduce the risk of Listeria contamination in food products ae some factors that drive the listeria monocytogenes infection treatment market in the North America.
As the number of reported Listeria monocytogenes infections rises, there is a corresponding increase in the demand for effective treatment options to manage and combat these infections, driving the market for Listeria infection treatments. For instance, in April 2024, the CDC began investigating a multistate outbreak of listeria monocytogenes linked to queso fresco and cotija cheese. As of April 10, 2024, the outbreak has resulted in 26 reported illnesses, with 23 individuals hospitalized and 2 fatalities.
Similarly, On July 8, 2024, a food recall warning was issued by Public Health Agency of Canada for various silk and great value brand plant-based refrigerated beverages for whch 15 people was hospitalized and 3 dealth. The presence of the listeria monocytogenes outbreak strain was confirmed within the production environment of the beverages.
Thus the continous outbreak of the listeria monocytogenes infection in the North America is accelerating demand for the effective treatment and is likely to drive the market growth in the region.
Listeria Monocytogenes Infection Treatment Industry Overview
The listeria monocytogenes infection treatment market is fragmented in nature due to the presence of several companies operating globally as well as regionally. Each entity contributes to this fragmentation through unique innovations, regional launches, partnerships with diverse organizations, and promotions across various leading platforms. Some of the key players operating in the market are Pfizer Inc., Novartis AG, Sanofi S.A., Dr. Reddy's Laboratories, AstraZeneca PLC, GlaxoSmithKline PLC, Cipla Ltd, Lupin Limited, Mylan N.V., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd. among others.
Listeria Monocytogenes Infection Treatment Market Leaders
-
Pfizer, Inc.
-
Teva Pharmaceutical Industries Ltd.
-
Sun Pharmaceutical Industries Limited
-
Cipla Ltd
-
Novartis AG
*Disclaimer: Major Players sorted in no particular order
Listeria Monocytogenes Infection Treatment Market News
- September 2024: The United States Food and Drug Administration and the United States Department of Agriculture have granted GRAS (Generally Recognized as Safe) status to INNEO, Innodal biotechnology flagship product, a food processing aid made to eliminate Listeria monocytogenes.
- April 2023: Gold Standard Diagnostics, a provider of diagnostic test systems and services in the United States, has unveiled its latest offering; Microgen Listeria-ID. This innovative tool is primarily designed to detect listeria monocytogenes, ensuring stringent quality control and monitoring in food processing facilities.
Listeria Monocytogenes Infection Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Number of Reported Listeria Monocytogenes Infections
4.2.2 Advanced in Diagnostic Technologies
4.3 Market Restraints
4.3.1 Lack of Targeted Therapies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Treatment
5.1.1 Drug
5.1.1.1 Sulfonamide Antibiotics
5.1.1.2 Ampicillin
5.1.1.3 Gentamicin
5.1.1.4 Vancomycin
5.1.1.5 Others
5.1.2 Surgery
5.2 By Disease Form
5.2.1 Invasive Listeriosis
5.2.2 Non-invasive Listeriosis
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Novartis AG
6.1.3 Sanofi S.A.
6.1.4 AstraZeneca PLC
6.1.5 Cipla Ltd
6.1.6 Sun Pharmaceutical Industries Limited
6.1.7 Teva Pharmaceutical Industries Ltd
6.1.8 Lupin Limited
6.1.9 Mylan N.V.
6.1.10 Dr. Reddy's Laboratories
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Listeria Monocytogenes Infection Treatment Industry Segmentation
As per the scope of the report, listeria monocytogenes infection is a rare disease. Listeria monocytogenes infection is a serious bacterial infection caused by the bacterium Listeria monocytogenes. This pathogen is commonly found in soil, water, and some animals. Listeria can contaminate a variety of foods, including raw vegetables, meats, and dairy products.
The Listeria Monocytogenes Infection Treatment market is segmented as by treatment, disease form and distribution. In term of treatment the market is segmented into drug and surgery. In drug type, the market is further segmented as sulfonamide antibiotics, ampicillin, gentamicin, vancomycin and others. In terms of disease form, the market is segmented as invasive listeriosis and non-invasive listeriosis. By Geography the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD) for the above segments.
| By Treatment | |||||||
| |||||||
| Surgery |
| By Disease Form | |
| Invasive Listeriosis | |
| Non-invasive Listeriosis |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Listeria Monocytogenes Infection Treatment Market Research FAQs
How big is the Listeria Monocytogenes Infection Treatment Market?
The Listeria Monocytogenes Infection Treatment Market size is expected to reach USD 452.30 million in 2024 and grow at a CAGR of 4.35% to reach USD 559.51 million by 2029.
What is the current Listeria Monocytogenes Infection Treatment Market size?
In 2024, the Listeria Monocytogenes Infection Treatment Market size is expected to reach USD 452.30 million.
Who are the key players in Listeria Monocytogenes Infection Treatment Market?
Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd and Novartis AG are the major companies operating in the Listeria Monocytogenes Infection Treatment Market.
Which is the fastest growing region in Listeria Monocytogenes Infection Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Listeria Monocytogenes Infection Treatment Market?
In 2024, the North America accounts for the largest market share in Listeria Monocytogenes Infection Treatment Market.
What years does this Listeria Monocytogenes Infection Treatment Market cover, and what was the market size in 2023?
In 2023, the Listeria Monocytogenes Infection Treatment Market size was estimated at USD 432.62 million. The report covers the Listeria Monocytogenes Infection Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Listeria Monocytogenes Infection Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Listeria Monocytogenes Infection Treatment Industry Report
Statistics for the 2024 Listeria Monocytogenes Infection Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Listeria Monocytogenes Infection Treatment analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
